EMA Talks the ‘Conflicts of Interest’ Talk, but Will it Walk the Walk?

Press Statement | 18 October 2010 | PDF

The European Medicines Agency (EMA) has taken a step in the right direction by adopting an improved policy to handle potential conflicts of interest among its scientific committee members and experts. Independence in scientific and expert advice is crucial to balanced decision making. Conflicts of interest (CoI) can bias regulatory affairs, and compromised decisions could result in the market approval of medicines of questionable efficacy or unproven safety, which would ultimately put citizens at risk.

Read more…

START TYPING AND PRESS ENTER TO SEARCH